myeloid derived suppressor cells as therapeutic target in hematological malignancies
;Kim eDe Veirman;Els eVan Valckenborgh;Qods eLahmar;Qods eLahmar;Xenia eGeeraerts;Xenia eGeeraerts;Elke eDe Bruyne;Eline eMenu;Ivan eVan Riet;Ivan eVan Riet;Karin eVanderkerken;Jo A Van Ginderachter;Jo A Van Ginderachter
international journal of heat and technology2014Vol. 4pp. -
204
veirman2014frontiersmyeloid
Abstract
Myeloid derived suppressor cells (MDSC) are a heterogeneous population of immature myeloid cells that accumulate during pathological conditions such as cancer and are associated with a poor clinical outcome. MDSC expansion hampers the host anti-tumor immune response by inhibition of T cell proliferation, cytokine secretion and recruitment of regulatory T cells. In addition, MDSC exert non-immunological functions including the promotion of angiogenesis, tumor invasion and metastasis. Recent years, MDSC are considered as a potential target in solid tumors and hematological malignancies to enhance the effects of currently used immune modulating agents. This review focuses on the characteristics, distribution, functions, cell-cell interactions and targeting of MDSC in hematological malignancies including multiple myeloma, lymphoma and leukemia.